Is CTSO's Q2 2024 EPS surge a sign of long-term growth?

**CTSO's Q2 2024 EPS surge is not a reliable indicator of long-term growth.** Here's why: 1. **Q2 2024 EPS Calculation**: The calculation of CTSO's Q2 2024 EPS is based on the most recent data available, which shows a negative EPS of $0.08. This negative figure suggests that the company may have incurred losses during the period, which is typically not indicative of growth. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |CTSO|CTSO.O|Cytosorbents|2023 Q3|25.00000000000001|-0.21|186| |CTSO|CTSO.O|Cytosorbents|2024 Q1|29.41176470588236|-0.12|186| |CTSO|CTSO.O|Cytosorbents|2024 Q2|42.85714285714286|-0.08|186| 2. **Analyst Forecasts**: Analysts at B. Riley have forecasted a Q2 2024 earnings per share (EPS) of -$0.09. This forecast indicates a potential decrease in earnings, which is inconsistent with the idea of long-term growth. 3. **Stock Ratings and Price Target**: Despite the negative earnings outlook, B. Riley has reaffirmed a "buy" rating on Cytosorbents' stock with a price target of $3.00. This suggests that the analysts believe there is potential for the stock to increase in value, but this does not necessarily mean that the EPS surge indicates long-term growth. 4. **Research Coverage and Ratings**: Research analysts at StockNews.com have initiated coverage on Cytosorbents with a "hold" rating. This neutral rating does not provide a clear indication of long-term growth. 5. **Institutional Activity**: Raymond James & Associates have bought 50,000 shares of Cytosorbents, indicating some institutional confidence in the company. However, this action alone does not provide a definitive answer regarding long-term growth. In conclusion, the Q2 2024 EPS surge, if it were to occur, would need to be evaluated in the context of the overall financial health of the company, including the opinions of analysts and institutional actions. Without a clear indication of improving financial performance and growth over subsequent quarters, a single quarter's EPS surge cannot be considered a reliable sign of long-term growth.